An expert review on breaking barriers in severe asthma in Brazil: Time to act

被引:5
作者
Pitrez, Paulo Marcio [1 ]
Giavina-Bianchi, Pedro [2 ]
Rizzo, Jose Angelo [3 ]
Souza-Machado, Adelmir [4 ,5 ]
Garcia, Guilherme Freire [6 ]
Menezes Pizzichini, Marcia Margaret [7 ]
机构
[1] Hosp Moinhos de Vento, Pediat Pulmonol Div, Rua Ramiro Barcelos 630-917, BR-90035001 Porto Alegre, RS, Brazil
[2] Univ Sao Paulo, Clin Immunol & Allergy Div, Fac Med, Sao Paulo, Brazil
[3] Univ Fed Pernambuco, Hosp Clin, Head Pneumol Dept, Recife, PE, Brazil
[4] Univ Fed Bahia, Inst Hlth Sci, Salvador, BA, Brazil
[5] Univ Fed Bahia, Program Asthma Control Bahia ProAR, Salvador, BA, Brazil
[6] Fundacao Hosp Minas Gerais FHEMIG, Belo Horizonte, MG, Brazil
[7] Univ Fed Santa Catarina, Florianopolis, SC, Brazil
关键词
Severe asthma; public health system; Brazil; innovative therapies; INHALED CORTICOSTEROIDS; IMPACT; PREVALENCE; MANAGEMENT; ALLERGIES; THERAPY; PHASE-3; BENRALIZUMAB; MEPOLIZUMAB; OMALIZUMAB;
D O I
10.1177/14799731211028259
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Currently, Brazil lacks a national asthma management program and is burdened with nearly 200,000 hospitalizations due to the disease per year and approximately 5 deaths per day. The purpose of this article was to analyze the current issues surrounding severe asthma in Brazil, as the status of diagnosis and treatment is largely unknown, and to provide feasible recommendations to elicit imminent action. A panel of Brazilian medical experts in the field of severe asthma was provided with a series of relevant questions to address prior to a multi-day conference. Within this conference, each narrative was discussed and edited by the entire group. Through numerous rounds of discussion consensus was achieved. In order to overcome barriers to adequate asthma treatment, this panel recommends specific initiatives that can be implemented in the short-term to decrease the burden of severe asthma in Brazil. With increasing healthcare costs and limited resources globally, there is an opportunity to implement these recommendations in other countries in order to achieve adequate asthma care. Severe asthma is a heterogeneous and complex disease with various phenotypes that requires strict attention for diagnosis and management. Although this disease affects only a small proportion of the population with asthma, it poses a great burden to healthcare systems. Thus, barriers to diagnosis, treatment, and management should be overcome as quickly and efficiently as possible.
引用
收藏
页数:11
相关论文
共 71 条
  • [1] Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma
    Aaron, Shawn D.
    Vandemheen, Katherine L.
    FitzGerald, J. Mark
    Ainslie, Martha
    Gupta, Samir
    Lemiere, Catherine
    Field, Stephen K.
    McIvor, R. Andrew
    Hernandez, Paul
    Mayers, Irvin
    Mulpuru, Sunita
    Alvarez, Gonzalo G.
    Pakhale, Smita
    Mallick, Ranjeeta
    Boulet, Louis-Philippe
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (03): : 269 - 279
  • [2] Point-of-care biomarkers in asthma management: Time to move forward
    Alving, Kjell
    Diamant, Zuzana
    Lucas, Sarah
    Magnussen, Helgo
    Pavord, Ian D.
    Piacentini, Giorgio
    Price, David
    Roche, Nicolas
    Sastre, Joaquin
    Thomas, Mike
    Usmani, Omar
    Bjermer, Leif
    [J]. ALLERGY, 2020, 75 (04) : 995 - 997
  • [3] Abdominal wall hernia in cirrhotic patients: emergency surgery results in higher morbidity and mortality
    Andraus, Wellington
    Pinheiro, Rafael Soares
    Lai, Quirino
    Haddad, Luciana B. P.
    Nacif, Lucas S.
    D'Albuquerque, Luiz Augusto C.
    Lerut, Jan
    [J]. BMC SURGERY, 2015, 15
  • [4] [Anonymous], 2012, J Bras Pneumol, V38, pS155
  • [5] [Anonymous], Asthma Control Test | Asthma Singapore
  • [6] Asher MI, 1998, EUR RESPIR J, V12, P315
  • [7] INTERNATIONAL STUDY OF ASTHMA AND ALLERGIES IN CHILDHOOD (ISAAC) - RATIONALE AND METHODS
    ASHER, MI
    KEIL, U
    ANDERSON, HR
    BEASLEY, R
    CRANE, J
    MARTINEZ, F
    MITCHELL, EA
    PEARCE, N
    SIBBALD, B
    STEWART, AW
    STRACHAN, D
    WEILAND, SK
    WILLIAMS, HC
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (03) : 483 - 491
  • [8] Austrialian Government Department of Health, 2017, PHARM BEN SCH PBS OM
  • [9] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
    Bel, Elisabeth H.
    Wenzel, Sally E.
    Thompson, Philip J.
    Prazma, Charlene M.
    Keene, Oliver N.
    Yancey, Steven W.
    Ortega, Hector G.
    Pavord, Ian D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) : 1189 - 1197
  • [10] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Chanez, Pascal
    Papi, Alberto
    Weinstein, Steven F.
    Barker, Peter
    Sproule, Stephanie
    Gilmartin, Geoffrey
    Aurivillius, Magnus
    Werkstrom, Viktoria
    Goldman, Mitchell
    [J]. LANCET, 2016, 388 (10056) : 2115 - 2127